Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension
Authors:
Open Access
- 22 January 2024
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (4) , 1726-1741
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Phosphodiesterase 4-targeted treatments for autoimmune diseasesBMC Medicine, 2013
- Tie2-mediated loss of peroxisome proliferator-activated receptor-γ in mice causes PDGF receptor-β-dependent pulmonary arterial muscularizationAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiationRespiratory Research, 2009
- Effects of Roflumilast, a Phosphodiesterase-4 Inhibitor, on Hypoxia- and Monocrotaline-Induced Pulmonary Hypertension in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Tadalafil Therapy for Pulmonary Arterial HypertensionCirculation, 2009
- Hypoxia Selectively Activates the CREB Family of Transcription Factors in the In Vivo LungAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitorsBiochemical and Biophysical Research Communications, 2005
- Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertensionThe FASEB Journal, 2001
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988